Pharmacological profile of ritanserin: A very specific central serotonin S2‐antagonist
Drug Development Research 1988 F. Awouters, C. J. E. Niemegeers, Anton A. H. P. Megens et al. 139 citations
Abstract Ritanserin, a novel methylenepiperidine derivative, was studied in a wide range of common pharmacological tests mainly in rats. The lowest ED 50 , 0.0070 mg/kg, was obtained against tryptamine‐induced cyanosis. At 0.037 mg/kg, tryptamine‐induced bilateral clonic seizures were inhibited. Slightly higher doses, up to 0.11 mg/kg, inhibited mescaline and 5‐hydroxytryptophan (5‐HTP)‐induced...